Intravenous ketamine infusion for a patient with treatment-resistant major depression: a 10-month follow-up

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

What is known and objective: Ketamine in a subanaesthetic dose has been shown to produce rapid antidepressant effects. Here, we describe a long-term follow-up case of a Korean patient with severe major depression who received repeated ketamine intravenous therapy (KIT). Case description: A 49-year-old woman with a 6-year history of treatment-resistant major depression was given KIT once every 1 or 2 weeks over 10 months, for a total of 36 treatments. Her mood stabilized, and she showed a nearly 50% reduction in the severity of her depressive symptom. What is new and conclusion: Long-term repeated KIT may be an option for alleviating treatment-resistant and relapsing major depression. Further research and large clinical trials are needed on the optimum KIT protocol, including dose, dosing interval, total number of treatments and when to stop.

Original languageEnglish
Pages (from-to)581-583
Number of pages3
JournalJournal of Clinical Pharmacy and Therapeutics
Volume43
Issue number4
DOIs
StatePublished - Aug 2018

Keywords

  • intravenous infusion
  • ketamine
  • major depression

Fingerprint

Dive into the research topics of 'Intravenous ketamine infusion for a patient with treatment-resistant major depression: a 10-month follow-up'. Together they form a unique fingerprint.

Cite this